Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.050
+0.058 (5.79%)
Dec 26, 2024, 10:45 AM EST - Market open
Biofrontera Employees
As of December 31, 2023, Biofrontera had 85 total employees, including 83 full-time and 2 part-time employees. The number of employees increased by 4 or 4.94% compared to the previous year.
Employees
85
Change (1Y)
4
Growth (1Y)
4.94%
Revenue / Employee
$415,976
Profits / Employee
-$151,024
Market Cap
8.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 85 | 4 | 4.94% |
| Dec 31, 2022 | 81 | 12 | 17.39% |
| Dec 31, 2021 | 69 | 13 | 23.21% |
| Dec 31, 2020 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 380 |
| T2 Biosystems | 113 |
| Mustang Bio | 80 |
| Dominari Holdings | 28 |
| Genprex | 26 |
| Elevai Labs | 18 |
| Virax Biolabs Group | 17 |
| Aethlon Medical | 14 |
BFRI News
- 3 days ago - Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - GlobeNewsWire
- 22 days ago - Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Accesswire
- 4 weeks ago - Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewsWire
- 5 weeks ago - Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Accesswire
- 2 months ago - Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire
- 2 months ago - Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire